Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Royal Philips (NYSE: PHG) has been recognized in Gartner's reports on digital health platforms, highlighting its HealthSuite Platform's ability to connect data across the care continuum. By 2024, Gartner predicts that early adopters of digital health platforms will significantly enhance their digital transformation speed. Philips' platform boasts over 100 integrated medical devices and securely archives 145 billion clinical images, emphasizing its focus on improving clinical workflows and operational insights through AI and data analytics.
Royal Philips (NYSE: PHG) announced research affirming the efficacy of its BioTel Heart MCOT for detecting atrial fibrillation (AF) post-cryptogenic stroke. The study demonstrated that MCOT detected 4.6 times more AF cases than the implantable loop recorder (ILR) alone. Implementing MCOT resulted in an average cost reduction of $198,909 per patient, illustrating significant savings and improved detection rates. This research validates the 30-day MCOT program as a cost-effective standard of care for cryptogenic stroke patients, potentially averting further strokes through timely intervention.
On February 22, 2022, Royal Philips (NYSE: PHG) reported significant ESG achievements for 2021. The company improved the lives of 1.7 billion people, with 167 million in underserved communities. Circular revenues constituted 16% of sales, driven by healthcare informatics and services. Philips maintained its carbon neutrality in operations, reducing CO2 emissions by 12%. The firm aims for 50% of suppliers to commit to science-based targets by 2025. Additionally, Philips reported a 29% waste reduction compared to 2020, highlighting its commitment to sustainability.
Summary not available.
Royal Philips (NYSE: PHG) announced that its Philips Enterprise Viewer – Vue Motion and EMR Tasy have received the 2022 Best in KLAS awards, marking a significant achievement in health technology. Vue Motion was recognized as the best Universal Viewer for the fifth consecutive year, while EMR Tasy won for Acute Care EMR in Latin America. These awards highlight Philips’ commitment to advancing digital health transformation and improving patient care through innovative informatics solutions.
Summary not available.
Royal Philips has enhanced its Lumify handheld ultrasound technology by introducing Pulse Wave Doppler, enabling comprehensive hemodynamic assessments for various medical professionals, including cardiologists and emergency care doctors. This upgrade allows for better quantification of blood flow and improved diagnostics across multiple specialties. Additionally, Lumify becomes the first handheld ultrasound to offer B-lines software, assisting in heart and lung evaluations, particularly for severe COVID-19 cases. This innovation aims to increase access to quality healthcare in underserved communities.
Royal Philips (NYSE: PHG) has entered a 10-year partnership with University Hospital Brandenburg an der Havel, valued at approximately EUR 18 million, to enhance its healthcare capabilities. This collaboration focuses on the supply of advanced diagnostic imaging solutions, including ultrasound and MRI, alongside the upgrading of hybrid operating rooms and interventional suites. The agreement also involves training and education for medical staff, aiming to improve patient outcomes and streamline operations.
Philips has launched the first full-service, at-home, 12-lead ECG solution tailored for decentralized clinical trials. This clinical-grade ECG aims to enhance patient recruitment, compliance, and retention by minimizing the necessity for site visits. With data readings comparable to traditional site-based ECGs, the innovative solution utilizes the PCA 500 ECG patch for secure, real-time data transmission. Philips’ advanced monitoring services have supported over 2,000 clinical trials globally. This new offering is already available in select markets across North America, Europe, and Asia.
On January 24, 2022, Royal Philips reported a challenging fourth quarter with sales of EUR 4.9 billion, reflecting a 10% comparable sales decline. The decline was attributed to supply chain challenges and COVID-19 related factors. Though income from continuing operations decreased to EUR 139 million from EUR 508 million in Q4 2020, adjusted EBITA stood at EUR 647 million, marking a drop from the previous year. Positive trends were seen in Diagnosis & Treatment with 4% order intake growth. For 2021, overall sales were EUR 17.2 billion, impacted by a decline in Connected Care. A dividend of EUR 0.85 per share was proposed.